Tempus ECG-AF vs Rhythm360

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Tempus AI, Inc.
VS
by RhythmScience

AI Verdict

Tempus ECG-AF is an AI-powered diagnostic tool focused on predicting the risk of new-onset atrial fibrillation from a single ECG. In contrast, Rhythm360 is a comprehensive platform designed to aggregate and manage data from various cardiac monitoring devices, providing operational efficiencies and insights across multiple cardiac conditions. While both leverage AI in cardiology, Tempus targets early risk identification, whereas Rhythm360 optimizes the management of existing patient monitoring data.

Choose Tempus ECG-AF if…

Choose Tempus ECG-AF if your primary goal is to proactively identify older patients (65+) at increased risk of developing new-onset atrial fibrillation within the next year, based on a standard 12-lead ECG. This tool is ideal for integrating into routine geriatric or internal medicine screenings to support earlier intervention and follow-up before symptoms manifest.

View Tempus ECG-AF →

Choose Rhythm360 if…

Choose Rhythm360 if you need a comprehensive, vendor-neutral platform to aggregate and manage cardiac monitoring data from a diverse range of devices for patients with existing or complex cardiac conditions. This solution is best suited for clinics aiming to reduce alert fatigue, streamline workflows, automate billing, and gain actionable AI-driven insights across hypertension, heart failure, and rhythm management.

View Rhythm360 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Tempus ECG-AF Rhythm360
Pricing Contact vendor Flexible pricing model that scales with clinic size and platform usage.
Deployment Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. Cloud-based SaaS platform
BAA Available Yes AI-estimated Yes AI-estimated
FDA Status Yes AI-estimated Unknown
HIPAA Yes AI-estimated Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Rhythm360

Rhythm360 offers a more comprehensive and flexible user experience with its cloud-based SaaS platform, mobile application for clinicians, and vendor-neutral data aggregation across various cardiac devices. Tempus ECG-AF, while integrated into healthcare facility systems, is described as not having a dedicated user interface and relies on integration with specific ECG systems, which might limit direct user interaction and flexibility.

Clinical Value

Rhythm360

While Tempus ECG-AF provides a specific, FDA-cleared predictive diagnostic for AF risk with strong validation, Rhythm360 demonstrates broader clinical impact across multiple cardiac conditions, including hypertension, heart failure, and rhythm management. Its integration of a validated HF-AI algorithm, showing significant reductions in hospitalizations and improved medication adherence, coupled with its ability to reduce alert fatigue and accelerate critical alert response times, suggests a more comprehensive and impactful clinical value across a wider patient population and care continuum.

Pricing & Value

Rhythm360

While Tempus ECG-AF has a clear, established CMS reimbursement pathway with a specific rate, Rhythm360 offers a flexible, scalable SaaS model with automated CPT code documentation and billing for a wider range of remote monitoring services. This comprehensive billing automation, coupled with claims of significant revenue increases for practices, suggests a stronger overall value proposition and clearer return on investment for a broader set of cardiology services.

Enterprise Readiness

Rhythm360

Rhythm360 demonstrates superior enterprise readiness through its cloud-based SaaS model, extensive bi-directional EHR integrations with major systems, and vendor-neutral data aggregation from all major cardiac device OEMs. This broad interoperability and robust data management capabilities make it highly adaptable and scalable for diverse and large healthcare enterprises.

Innovation

Tie

Both tools exhibit significant innovation in their respective domains. Tempus ECG-AF is highly innovative for its specific, FDA-cleared predictive AI algorithm that identifies future AF risk from a standard ECG, representing a breakthrough in proactive diagnostics. Rhythm360 demonstrates innovation through its comprehensive AI-powered platform that unifies disparate cardiac data, employs AI for alert triage and data normalization, and integrates advanced predictive algorithms for heart failure management, revolutionizing workflow and patient care across a broader spectrum of cardiology.

Support & Docs

Rhythm360

Rhythm360 explicitly offers optional 24/7/365 oversight by certified cardiac technicians, a comprehensive knowledge base, and dedicated implementation support with training. Tempus provides standard customer support via email and phone during business hours, but lacks the specific, continuous clinical oversight and detailed documentation resources highlighted by Rhythm360.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Tempus ECG-AF Rhythm360
Name Tempus ECG-AF Rhythm360
Company Tempus AI, Inc. RhythmScience
Description FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. AI-powered integrated platform that unifies cardiac monitoring data from various devices, providing actionable insights for hypertension, heart failure, and rhythm management, and reducing alert fatigue.
Key Features AI-based algorithm for 12-lead ECG analysis; Detects signs associated with new onset Atrial Fibrillation (AF) within 12 months; Intended for patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery; Results interpreted in conjunction with other diagnostic information and clinical history; Compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems; Trained on over 1.5 million ECGs from over 500,000 patients Vendor-neutral data aggregation (all major OEMs: Medtronic, Boston Scientific, Abbott, Biotronik); AI-driven alert triage (80% faster response times, reduces alert fatigue); Bi-directional EHR integration (Epic, Cerner, Athenahealth, eClinicalWorks, GreenwayHealth, GE Centricity); Automated CPT code documentation and billing (e.g., 93298, 93299, 99454, 99453, 99457); HIPAA-compliant mobile application for clinicians; AI Data Normalization (API, HL7, XML, PDF parsing via computer vision); Optional 24/7/365 oversight by certified cardiac technicians (CCTs); Heart Failure Management (predictive algorithms, GDMT optimization)
Specialties Cardiology, Geriatrics, Internal Medicine Cardiology

Videos

Demos, reviews, and walkthroughs featuring Tempus ECG-AF and Rhythm360.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Tempus ECG-AF is an AI-based algorithm that analyzes 12-lead ECGs to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter within the next 12 months. Rhythm360 is an AI-powered integrated platform that unifies cardiac monitoring data from various devices to provide actionable insights for hypertension, heart failure, and rhythm management.
Tempus ECG-AF specifically analyzes 12-lead ECG recordings. Rhythm360 aggregates cardiac monitoring data from various devices, including major OEMs like Medtronic, Boston Scientific, Abbott, and Biotronik.
Tempus ECG-AF is a software solution integrated into healthcare facility systems and is compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems. Rhythm360 is a cloud-based SaaS platform offering bi-directional EHR integration with systems such as Epic, Cerner, Athenahealth, eClinicalWorks, GreenwayHealth, and GE Centricity.
Tempus ECG-AF has CMS reimbursement available with specific CPT codes (0764T and 0765T) to APC 5734, with a Medicare rate of $128.90 effective January 1, 2025. Rhythm360 offers automated CPT code documentation and billing for remote monitoring codes such as 93298, 93299, 99454, 99453, and 99457.
Tempus ECG-AF is intended for patients aged 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. Rhythm360 is designed for a broader population requiring cardiac monitoring for conditions like hypertension, heart failure, and rhythm management.
Tempus ECG-AF focuses on its AI-based algorithm for AF risk detection from ECGs. Rhythm360 offers optional 24/7/365 oversight by certified cardiac technicians (CCTs), a HIPAA-compliant mobile application for clinicians, and predictive algorithms for heart failure management and GDMT optimization.
AI Tool Finder
AI-powered search. Results may not be comprehensive.